Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
100.00%
Operating Margin
87.24%
Net Margin
11.54%
Efficiency Metrics
Revenue per Expense Ratio
7.84
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
-41.19%
Income Tax Rate
0.00%
EPS
0.1200000000
Balance Sheet Analysis
Current Ratio
3.06
Cash Ratio
0.00
Working Capital
$1.45M
Debt to Equity
0.69
Debt to Assets
40.67%
Equity Ratio
58.99%
Cash Flow Analysis
Operating Cash Flow Ratio
55.73%
Free Cash Flow Ratio
55.73%
CapEx to Revenue
0.00%
Dividends Paid
$7.63M
Stock Buybacks
No buybacks
Total Shareholder Returns
$7.63M
Cash Position Change
362,853,200.0%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
157.52%
Net Income
106.46%
EPS
106.42%
Operating Income
152.67%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
179.84%
Operating Cash Flow
-17.47%
Free Cash Flow
-17.47%
Balance Sheet Health
Assets
-2.91%
Debt
0.00%
Book Value per Share
-4.91%
Inventory
0.00%
Shareholder Returns
Dividends per Share
-22.64%
Shares Outstanding
0.00%
Long Term Trends
3Y Revenue/Share
11.36%
5Y Revenue/Share
288.82%
3Y Dividend/Share
-19.06%
5Y Dividend/Share
-23.76%